ArticlemAbs2025

Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis.

Jason P Lynch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.